# NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients

> **NCT06131424** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1151 (actual)

## Conditions studied

- HER2-negative

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06131424
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-23
- **Primary completion:** 2025-05-19
- **Final completion:** 2025-05-19
- **Target enrollment:** 1151 (ACTUAL)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06131424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06131424, "NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06131424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*